BACKGROUND: Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. The gene discussed is NR4A1; the disease is breast carcinoma.